We use cookies on accura.dk

accura.dk uses cookies to improve the user-friendliness and functionality. By using our website, you consent to our use of cookies. Read more about cookies at accura.dk. Enjoy.

Read more about our cookie policy and instructions to delete cookies


SSI concludes agreement with leading vaccine manufacturer concerning new tuberculosis test

Case info

Statens Serum Institut (SSI) has concluded an agreement with the Indian pharmaceutical group Serum Institute of India Pvt. Ltd. (SIIPL) concerning the commercialisation of a new test for diagnosing tuberculosis.

SIIPL is the world's largest vaccine manufacturer. Their vaccines are accredited by the World Health Organization and are being used in national immunisation programs in 170 countries worldwide.

It is estimated that more than 1.5 billion people are infected with tuberculosis. Each year, close to 10 million of these people develop tuberculosis and 1.5 million die (source: Statens Serum Institut). The new test may help diagnosing the many people who are unknowingly infected with the pulmonary disease. The test is the first test for diagnosing tuberculosis which is reliable and effective without blood sampling and laboratory analyses.

SSI has developed the test which SIIPL is to produce and distribute. The test is expected to be ready for the market within the next 12 months.

Read more here.

Dan Ermose and Henrik Juul Hansen advised SSI in connection with the negotiations and the drafting of the agreement.


Dan Ermose
Dan Ermose

Associate Partner, Attorney-at-Law, LL.M., CIPP/E

Mobile: +45 3078 6710

Henrik Juul Hansen
Henrik Juul Hansen

Partner, Attorney-at-Law

Mobile: +45 3078 6740

Accura's recent cases

We advise in connection with the largest and most complex transactions on the market.

Read a selection of our cases here.

Accura's recent cases

Accuras Life Science Team

Accuras Life Science Team

Read more about our advisory services on Life Sciences here.